Storia in 7 fonti

Biotech Goes Sky-High After LSD Drug Treats Depression

One analyst called this a "best-case" scenario for the company's experimental depression treatment.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo2 g fa

Biotech Goes Sky-High After LSD Drug Treats Depression

One analyst called this a "best-case" scenario for the company's experimental depression treatment.

originale

zerohedge.com3 g fa

Psychedelic Stocks Could Explode Higher

Definium's DT120 met Phase 3 for LSD-based depression therapy, driving DFTX +200% YTD with single-dose efficacy versus SSRIs. Policy-driven FDA expedited pathway opens M&A consolidation window; psychedelic therapeutics signal broader deregulation trend in healthcare.

Leggi questa versione → originale

gizmodo.com2 g fa

LSD Just Passed Its Biggest Test Yet for Treating Depression

Definium Therapeutics annuncia Phase III di DT120 (LSD proprietaria): singola dose raggiunge 35% remissione versus 7% placebo nella depressione clinica. Per manager tech il segnale è una terapia single-dose disruptive rispetto ai trattamenti cronici attuali, con impatto potenziale su employee wellness e healthcare spending aziendale.

Leggi questa versione → originale

statnews.com3 g fa

Definium LSD therapy helped patients with major depression in late-stage trial

Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the psychedelic drug closer to a potential approval.

Leggi questa versione → originale

benzinga.com1 g fa

What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)

Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signals the shares are currently overbought.

Leggi questa versione → originale

endpoints.news3 g fa

Definium reports Phase 3 hit for LSD drug in severe form of depression

Definium's LSD drug DT120 hit its Phase 3 MDD primary endpoint, beating analyst expectations with significant improvement in depression symptoms.

Leggi questa versione → originale

Biotech Goes Sky-High After LSD Drug Treats Depression

Confronto fonti

Biotech Goes Sky-High After LSD Drug Treats Depression

Psychedelic Stocks Could Explode Higher

LSD Just Passed Its Biggest Test Yet for Treating Depression

Definium LSD therapy helped patients with major depression in late-stage trial

What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)

Definium reports Phase 3 hit for LSD drug in severe form of depression

Timeline cronologica

Psychedelic Stocks Could Explode Higher

Definium LSD therapy helped patients with major depression in late-stage trial

Definium reports Phase 3 hit for LSD drug in severe form of depression

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Biotech Goes Sky-High After LSD Drug Treats Depression

Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal

LSD Just Passed Its Biggest Test Yet for Treating Depression

What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)

To Wall Street, psychedelics biotechs are more teammates than rivals

Biotech Goes Sky-High After LSD Drug Treats Depression

Confronto fonti

Biotech Goes Sky-High After LSD Drug Treats Depression

Psychedelic Stocks Could Explode Higher

LSD Just Passed Its Biggest Test Yet for Treating Depression

Definium LSD therapy helped patients with major depression in late-stage trial

What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)

Definium reports Phase 3 hit for LSD drug in severe form of depression

Timeline cronologica

Psychedelic Stocks Could Explode Higher

Definium LSD therapy helped patients with major depression in late-stage trial

Definium reports Phase 3 hit for LSD drug in severe form of depression

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Biotech Goes Sky-High After LSD Drug Treats Depression

Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal

LSD Just Passed Its Biggest Test Yet for Treating Depression

What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)

To Wall Street, psychedelics biotechs are more teammates than rivals